의약품 수탁제조 시장 : 제조 제품 유형별, 원료의약품 유형별, 원료의약품 약리 활성별, FDF 유형별, 제형별, 포장 유형별, 사업 규모별, 최종사용자별, 지역별 : 산업 동향 및 세계 예측(-2035년)
Pharmaceutical Contract Manufacturing Market by Type of Product Manufactured, Type of API, API Potency, Type of FDF, Dosage Form, Type of Packaging Offered, Scale of Operation, End Users and Regions: Industry Trends and Global Forecasts, Till 2035
상품코드:1616879
리서치사:Roots Analysis
발행일:2024년 12월
페이지 정보:영문 545 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 의약품 수탁제조 시장 규모는 2035년까지 예측 기간 동안 4.3%의 CAGR로 확대되어 현재 990억 달러에서 2035년까지 1,560억 달러로 성장할 것으로 예상됩니다.
의약품 수탁제조 시장은 주로 제품 출시의 효율성과 유연성에 대한 수요로 인해 크게 성장하고 있습니다. 업무 전문성, 첨단 장비, 전문 시설 등의 요인으로 인해 아웃소싱이 증가하고 있습니다. 세계 CMO 및 CDMO에 제조 업무를 아웃소싱함으로써 기업은 공급망을 다변화하고 정치적, 경제적 불확실성에 따른 리스크를 줄일 수 있다는 점은 주목할 만합니다. 또한 자동화, 연속 생산, 데이터 분석과 같은 첨단 기술의 통합은 생산능력을 향상시키고 고품질의 결과를 보장합니다. 빠르게 진화하는 제약 산업에서 제약 위탁생산 업체들은 복잡한 규제 환경을 극복하고, 제조 워크플로우를 최적화하며, 임상시험에서 상업적 규모의 제조로 원활하게 전환할 수 있는 전문성을 보유하고 있습니다. 앞서 언급한 요인들은 예측 기간 동안 위탁 서비스 제공업체들에게 유리한 시장 성장 기회를 제공할 가능성이 높습니다.
본 보고서는 세계의 의약품 수탁제조 시장에 대해 조사했으며, 시장 개요와 함께 제조 제품 유형별, 원료의약품 유형별, 원료약리활성별, FDF 유형별, 제형별, 포장 유형별, 사업 규모별, 최종사용자별, 지역별 동향, 시장 진출 기업 프로파일 등을 정리하여 전해드립니다.
As per Roots Analysis, the global pharmaceutical contract manufacturing market is estimated to grow from USD 99 billion in the current year to USD 156 billion by 2035, at a CAGR of 4.3% during the forecast period, till 2035.
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Product Manufactured
API & Intermediates
FDF
Type of API
Originator API
Generic API
API Potency
Low Potent API
High Potent API
Type of FDF
Originator FDF
Generic FDF
Dosage Form
Oral Solids
Liquids
Emulsions
Other Dosage Forms
Type of Packaging Offered
Bottles
Blisters
Parenteral
Others
Scale of Operation
Clinical
Commercial
Type of End-user
Small Companies
Mid-sized Companies
Large and Very Large Companies
Key Geographical Regions
North America
Europe
Asia-Pacific
Latin America
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS
The pharmaceutical contract manufacturing market is poised for significant growth, primarily driven by the demand for efficiency and flexibility in bringing products to the market. Factors such as operational expertise, advanced equipment and specialized facilities have led to an increase in outsourcing operations. It is worth highlighting that by outsourcing manufacturing operations to CMOs and CDMOs with a global footprint, companies can diversify their supply chains and reduce risks associated with political and economic uncertainties. Moreover, the integration of advanced technologies, such as automation, continuous manufacturing and data analytics, boosts production capabilities and ensures high-quality outcomes. With the rapidly evolving pharmaceutical landscape, contract manufacturers bring expertise in navigating complex regulatory frameworks, optimizing production workflows, and supporting a seamless transition from clinical studies to commercial scale manufacturing. The aforementioned factors are likely to present lucrative market growth opportunities for contract service providers during the forecast period.
The report delves into the current state of the pharmaceutical contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:
1. Presently, close to 425 organizations offer pharmaceutical contract manufacturing services; of these, majority of the CMOs provide fill-finish / packaging and labelling services.
2. A relatively larger proportion of CMOs manufacture FDFs; close to 15% of the players have the required capabilities to manufacture all types of finished dosage forms.
3. In pursuit of building a competitive edge and to establish themselves as one-stop shops, stakeholders are actively consolidating their capabilities related to small molecule manufacturing through mergers and acquisitions.
4. In order to meet the rising demand for APIs and finished products, CMOs have made elaborate investments in expanding their existing capacities and capabilities; this trend is most pronounced in the US and India.
5. The global pharmaceutical contract manufacturing capacity is well distributed across different facilities worldwide; notably, large and very large players account for 80% of the total capacity.
6. Owing to the increase in outsourcing activity for small molecule manufacturing operations, the demand for pharmaceutical contract manufacturing is anticipated to rise significantly over the decade.
7. In the past decade, a shift in trend has been observed in the pharmaceutical contract manufacturing industry as more players have set up their manufacturing facilities in developing regions across Asia-Pacific.
8. Driven by the increasing pace of expansions and mergers between the stakeholders in this domain, the market for pharmaceutical contract manufacturing is poised to witness steady growth in the foreseeable future.
9. The pharmaceutical contract manufacturing market is anticipated to grow at a steady rate, till 2035; North America is expected to capture the majority share (over 35%) of the market by 2035.
10. In the long term, small and mid-sized companies are likely to drive the growth of the pharmaceutical contract manufacturing market; oral solids is expected to capture the majority share (~50%) by 2035.
FDF segment is Likely to Dominate the Pharmaceutical Contract Manufacturing Market During the Forecast Period
Based on the type of product manufactured, the market is segmented into API & Intermediates and FDF. It is worth highlighting that majority of the current pharmaceutical contract manufacturing market is captured by the FDF segment and this trend is likely to remain the same in the forthcoming years. This can be attributed to the growing demand for ready-to-make products, high value addition and stringent regulatory guidelines.
Currently, Generic and Originator APIs Hold Similar Market Share of the Pharmaceutical Contract Manufacturing Market
Based on the type of APIs, the market is segmented into generic API and originator API. It is worth highlighting that, at present, both generic and originator APIs capture almost similar market share in the pharmaceutical contract manufacturing market. This can be attributed to competitive pricing and quality standards maintained by generic manufacturers. It is worth noting that there is continued demand for branded drugs from originator companies.
High Potent API Segment is the Fastest Growing Segment of the Pharmaceutical Contract Manufacturing Market
Based on the types of API by potency, the market is segmented into low potent API and high potent API. Owing to their enhanced efficacy, lower dosage requirements and increasing demand for targeted therapies, the highly potent API (HPAPI) market is likely to grow at a relatively higher CAGR.
Currently, Originator FDF Occupies the Largest Share of the Pharmaceutical Contract Manufacturing Market
Based on the type of FDFs, the market is segmented into generic FDF and originator FDF. Owing to brand loyalty, ongoing investments in research and development, and established market presence, the originator FDF holds the maximum share within the pharmaceutical contract manufacturing market.
Liquid Dosage Form is the Fastest Growing Segment of the Pharmaceutical Contract Manufacturing Market
Based on the dosage forms, the market is segmented into oral solids, liquids, emulsions and others. It is worth highlighting that, due to the simplicity of administration, growing applications in pediatric and geriatric populations and enhanced patient adherence, liquids are likely to grow at a higher CAGR in the forthcoming years.
Currently, Bottles Occupy the Largest Share of the Pharmaceutical Contract Manufacturing Market
Based on the type of packaging offered, the market is segmented into bottles, blisters, parenterals and others. It is worth highlighting that, at present, bottles hold the maximum share within the pharmaceutical contract manufacturing market. Bottles offer various advantages, such as cost-effectiveness, versatility and capability to accommodate various types of formulations and dosages.
By Scale of Operation, Commercial Scale is Likely to Dominate the Pharmaceutical Contract Manufacturing Market
Based on the scale of operation, the market is segmented into clinical and commercial scale. Whilst commercial scale manufacturing will be the primary driver of the overall market, it is worth highlighting that the pharmaceutical contract manufacturing market at the clinical scale is likely to grow at a relatively higher CAGR.
Small Companies Account for the Largest Share of the Pharmaceutical Contract Manufacturing Market
Based on the type of end-user, the market is segmented into small, mid-sized, and large and very large companies. It is worth highlighting that, at present, small companies capture the highest share within the pharmaceutical manufacturing market. This trend is unlikely to change in the near future.
North America Accounts for the Largest Share of the Market
Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Majority share is expected to be captured by contract manufacturers based in North America. It is worth highlighting that over the years, the market for Asia-Pacific is expected to grow at a higher CAGR.
Example Players in the Pharmaceutical Contract Manufacturing Market
AMRI Global
Altasciences
Cambrex
Catalent
DPT Laboratories
Aenova
Almac
Corden Pharma
Fresenius Kabi
Glatt
Hovione
Recipharm
Siegfried
CMIC Group
Nectar Lifesciences
Syngene
WuXi AppTec
Primary Research Overview
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:
Former Director of Business Development, Ajinomoto Althea
Former Chief Executive Officer, Bachem
President and Chief Executive Officer, CiVentiChem
Digitalization and Artificial Intelligence Manager, CordenPharma
Former Director, Commercial Development, Helsinn Group
Former Director, Pharmaceuticals Marketing, Novasep
Director, Operations, Sovereign Pharma
Former Vice President Business Development, Marketing, and IP, Wavelength Pharmaceuticals
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE
Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the pharmaceutical contract manufacturing market, focusing on key market segments, including [A] type of product manufactured, [B] type of API, [C] API potency, [D] type of FDF, [E] dosage form, [F] type of packaging offered, [G] scale of operation, [H] end users and [I] key geographical regions.
Regulatory Landscape: A discussion on general regulatory guidelines across different countries, featuring an elaborative assessment of various CMOs in the pharmaceutical contract manufacturing industry, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. In addition, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
Market Landscape: A comprehensive evaluation of companies involved in contract manufacturing of small molecules, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facility, [E] type of manufacturer, [F] type of services offered, [G] type of finished dosage form manufactured, [H] type of packaging offered and [I] scale of operation.
Regional Capability Analysis: A detailed analysis of the capabilities of pharmaceutical contract manufacturing facilities in different regions (North America, Europe, Asia-Pacific and the Rest of the World) across the globe.
Company Profiles: In-depth profiles of key industry players in pharmaceutical contract manufacturing market, focusing on [A] company overviews, [B] manufacturing portfolio, [C] financial information, [D] recent developments and [E] an informed future outlook.
Additional Insights: An insightful framework that emphasizes the key indicators and factors that need to be considered by pharmaceutical drug developers to determine whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
Merger and Acquisitions: A comprehensive examination of the various mergers and acquisitions, focusing on multiple relevant parameters, including [A] year of agreement, [B] type of agreement, [C] key value drivers of the deal, [D] most active players (in terms of number of agreements signed) and [E] geographical location of the companies. In addition, the chapter provides information on the financial terms of the deals (if available) in order to enumerate the deal multiples (in terms of annual revenues of the acquired firm (at the time of acquisition) and years of experience in this domain).
Acquisitions: An analysis of acquisitions has taken place in the pharmaceutical contract manufacturing domain, since 2017.
Capacity Analysis: Estimation of global pharmaceutical manufacturing capacity, derived from data provided by various stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of [A] company size and [B] key geographical regions.
Demand Analysis: Informed estimates of the annual commercial and clinical demand for small molecule drugs across key geographical regions.
Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.
KEY QUESTIONS ANSWERED IN THIS REPORT
How many companies are currently engaged in this market?
Which are the leading companies in this market?
What is the current global demand for small molecules?
What percentage of the pharmaceutical manufacturing operations are presently outsourced?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older
TABLE OF CONTENTS
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation
2.7. Key Market Segmentations
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Types of Third-party Manufacturers
5.3. Overview of Pharmaceutical Contract Manufacturing
5.4. Evolution of Pharmaceutical Contract Manufacturing
5.4.1. Traditional Pharmaceutical CMOs
5.4.2. Modern Pharmaceutical CMOs
5.5. Need for Outsourcing in the Pharmaceutical Industry
5.6. Services Offered by CMOs
5.7. Key Considerations While Selecting a CMO
5.8. Risks and Challenges Associated with Outsourcing Pharmaceutical Manufacturing Operations
5.9. Recent Developments in the Pharmaceutical Contract Manufacturing Industry
7.2.4. Analysis by Location of Manufacturing Facility
7.2.5. Analysis by Product Manufacturing Capability
7.2.6. Analysis by Type of Product Manufactured
7.2.7. Analysis by Type of Service Offered
7.2.8. Analysis by Type of Finished Dosage Form Manufactured
7.2.9. Analysis by Type of Packaging Offered
7.2.10. Analysis by Scale of Operation
8. REGIONAL CAPABILITY
8.1. Chapter Overview
8.2. Key Assumptions and Methodology
8.3. Overall Landscape of Pharmaceutical Contract Manufacturing Facilities
8.3.1. Pharmaceutical Contract Manufacturing Facilities in North America
8.3.2. Pharmaceutical Contract Manufacturing Facilities in Europe
8.3.3. Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific
8.3.4. Pharmaceutical Contract Manufacturing Facilities in Rest of the World
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Pharmaceutical CMOs based in North America
9.2.1. AMRI Global
9.2.1.1. Company Overview
9.2.1.2. Service Portfolio
9.2.1.3. Recent Developments and Future Outlook
9.2.2. Altasciences
9.2.2.1. Company Overview
9.2.2.2. Service Portfolio
9.2.2.3. Recent Developments and Future Outlook
9.2.3. Cambrex
9.2.3.1. Company Overview
9.2.3.2. Service Portfolio
9.2.3.3. Recent Developments and Future Outlook
9.2.4. Catalent
9.2.4.1. Company Overview
9.2.4.2. Financial Information
9.2.4.3. Service Portfolio
9.2.4.4. Recent Developments and Future Outlook
9.2.5. DPT Laboratories
9.2.5.1. Company Overview
9.2.5.2. Service Portfolio
9.2.5.3. Recent Developments and Future Outlook
9.3. Pharmaceutical CMOs based in Europe
9.3.1. Aenova
9.3.1.1. Company Overview
9.3.1.2. Financial Information
9.3.1.3. Service Portfolio
9.3.1.4. Recent Developments and Future Outlook
9.3.2. Almac
9.3.2.1. Company Overview
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Recent Developments and Future Outlook
9.3.3. CordenPharma
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Recent Developments and Future Outlook
9.3.4. Fresenius Kabi
9.3.4.1. Company Overview
9.3.4.2. Financial Information
9.3.4.3. Service Portfolio
9.3.4.4. Recent Developments and Future Outlook
9.3.5. Glatt
9.3.5.1. Company Overview
9.3.5.2. Service Portfolio
9.3.5.3. Recent Developments and Future Outlook
9.3.6. Hovione
9.3.6.1. Company Overview
9.3.6.2. Service Portfolio
9.3.6.3. Recent Developments and Future Outlook
9.3.7. Recipharm
9.3.7.1. Company Overview
9.3.7.2. Financial Information
9.3.7.3. Service Portfolio
9.3.7.4. Recent Developments and Future Outlook
9.3.8. Siegfried
9.3.8.1. Company Overview
9.3.8.2. Financial Information
9.3.8.3. Service Portfolio
9.3.8.4. Recent Developments and Future Outlook
9.4. Pharmaceutical CMOs based in Asia-Pacific and Rest of the World
9.4.1. CMIC Group
9.4.1.1. Company Overview
9.4.1.2. Financial Information
9.4.1.3. Service Portfolio
9.4.1.4. Recent Developments and Future Outlook
9.4.2. Nectar Lifesciences
9.4.2.1. Company Overview
9.4.2.2. Financial Information
9.4.2.3. Service Portfolio
9.4.2.4. Recent Developments and Future Outlook
9.4.3. Syngene
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Service Portfolio
9.4.3.4. Recent Developments and Future Outlook
9.4.4. WuXi AppTec
9.4.4.1. Company Overview
9.4.4.2. Financial Information
9.4.4.3. Service Portfolio
9.4.1.4. Recent Developments and Future Outlook
10. SHORT PROFILES
10.1. Chapter Overview
10.2. Players based in North America
10.2.1. Albemarle
10.2.2. Baxter
10.2.3. Patheon
10.2.4. West Pharmaceutical Services
10.3. Players based in Europe
10.3.1. Eurofins Scientific
10.3.2. Evonik
10.3.3. Fareva
10.3.4. GlaxoSmithKline
10.3.5. Lonza
10.4. Players based in Asia-Pacific and Rest of the World
10.4.1. Alkem Laboratories
10.4.2. Aspen Pharmacare
10.4.3. MSN Laboratories
10.4.4. Teva Pharmaceuticals
10.4.5. UBE Corporation
11. MAKE VERSUS BUY DECISION FRAMEWORK
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Pharmaceutical Contract Manufacturers: Make versus Buy Decision Making
11.3.1. Scenario 1
11.3.2. Scenario 2
11.3.3. Scenario 3
11.3.4. Scenario 4
11.4. Concluding Remarks
12. MERGERS AND ACQUISITIONS
12.1. Chapter Overview
12.2. Merger and Acquisition Models
12.3. Pharmaceutical Contract Manufacturing: Mergers and Acquisitions
12.3.1. Analysis by Year of Agreement
12.3.2. Analysis by Type of Agreement
12.3.3. Analysis by Type of Acquisition
12.3.4. Analysis by Focus Area
12.3.5. Analysis by Type of Business Segment
12.3.6. Analysis by Type of Service Offered
12.3.7. Analysis by Scale of Operation
12.3.8. Analysis by Geography
12.3.9. Analysis by Location of Manufacturing Facility
12.3.10. Analysis by Key Value Drivers
12.3.11. Analysis by Year of Acquisition and Key Value Drivers
12.3.12. Most Active Acquirers: Analysis by Number of Acquisitions
12.4. Key Acquisitions: Analysis by Deal Multiples
13. RECENT EXPANSIONS
13.1. Chapter Overview
13.2. Type of Expansions
13.2. Pharmaceutical CMOs: Recent Expansions
13.2.1. Analysis by Year of Expansion
13.2.2. Analysis by Type of Expansion
13.2.3. Analysis by Purpose of Expansion
13.2.4. Analysis by Year and Purpose of Expansion
13.2.5. Analysis by Type of Business Segment
13.2.6. Analysis by Type of API Manufactured
13.2.7. Analysis by Type of Service Offered
13.2.8. Analysis by Scale of Operation
13.2.9. Analysis by Capital Invested
13.2.10. Analysis by Location of Headquarters
13.2.11. Analysis by Location of Manufacturing Facility
13.2.12. Most Active Players: Analysis by Number of Recent Expansions
14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Pharmaceutical Contract Manufacturing: Global Production Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Scale of Operation
14.3.2. Analysis by Location of Headquarters
14.3.3. Analysis by Location of Manufacturing Facilities
14.3.3.1. Pharmaceutical Contract Manufacturing Capacity in North America
14.3.3.2. Pharmaceutical Contract Manufacturing Capacity in Europe
14.3.3.3. Pharmaceutical Contract Manufacturing Capacity in Asia-Pacific
14.4. Concluding Remarks
15. DEMAND ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.2.1. Overall Annual Demand for Small Molecule APIs, till 2035
15.2.2. Annual Commercial Demand for Small Molecule APIs: Distribution by Geography, Current Year and 2035
15.2.2.1. Annual Commercial Demand for Small Molecule APIs in North America, till 2035
15.2.2.2. Annual Commercial Demand for Small Molecule APIs in Europe, till 2035
15.2.2.3. Annual Commercial Demand for Small Molecule APIs in Asia-Pacific, till 2035
15.2.2.4. Annual Commercial Demand for Small Molecule APIs in Rest of the World, till 2035
15.2.3. Annual Clinical Demand for Small Molecule APIs: Distribution by Trial Phase, Current Year and 2035
15.2.3.1. Annual Clinical Demand for Small Molecule APIs in Phase I Trials, till 2035
15.2.3.2. Annual Clinical Demand for Small Molecule APIs in Phase II Trials, till 2035
15.2.3.3. Annual Clinical Demand for Small Molecule APIs in Phase III Trials, till 2035
15.3. Annual Demand vs Capacity
16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion
17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Global Pharmaceutical Contract Manufacturing Market, Historical Trends (since 2017) and Forecasted Estimates (till 2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario
17.4. Key Market Segments
18. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF PRODUCT MANUFACTURED
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of Product Manufactured, Current Year and 2035
18.3.1. Pharmaceutical Contract Manufacturing Market for API and Intermediates: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
18.3.2. Pharmaceutical Contract Manufacturing Market for FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation
19. PHARMACEUTICAL API CONTRACT MANUFACTURING MARKET, BY TYPE OF API
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Pharmaceutical API Contract Manufacturing Market: Distribution by Type of API, Current Year and 2035
19.3.1. Pharmaceutical API Contract Manufacturing Market for Generic API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
19.3.2. Pharmaceutical API Contract Manufacturing Market for Originator API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation
20. PHARMACEUTICAL API CONTRACT MANUFACTURING MARKET, BY API POTENCY
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Pharmaceutical API Contract Manufacturing Market: Distribution by API Potency, Current Year and 2035
20.3.1. Pharmaceutical API Contract Manufacturing Market for Low Potent API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
20.3.2. Pharmaceutical API Contract Manufacturing Market for High Potent API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
20.4. Data Triangulation and Validation
21. PHARMACEUTICAL FDF CONTRACT MANUFACTURING MARKET, BY TYPE OF FDF
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Pharmaceutical FDF Contract Manufacturing Market: Distribution by Type of FDF, Current Year and 2035
21.3.1. Pharmaceutical FDF Contract Manufacturing Market for Generic FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
21.3.2. Pharmaceutical FDF Contract Manufacturing Market for Originator FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
21.4. Data Triangulation and Validation
22. PHARMACEUTICAL FDF CONTRACT MANUFACTURING MARKET, BY DOSAGE FORM
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Pharmaceutical FDF Contract Manufacturing Market: Distribution by Dosage Form, Current Year and 2035
22.3.1. Pharmaceutical FDF Contract Manufacturing Market for Oral Solids: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
22.3.2. Pharmaceutical FDF Contract Manufacturing Market for Liquids: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
22.3.3. Pharmaceutical FDF Contract Manufacturing Market for Emulsions: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
22.3.4. Pharmaceutical FDF Contract Manufacturing Market for Other Dosage Forms: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation
23. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF PACKAGING OFFERED
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of Packaging Offered, Current Year and 2035
23.3.1. Pharmaceutical Contract Manufacturing Market for Bottles: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
23.3.2. Pharmaceutical Contract Manufacturing Market for Blisters: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
23.3.3. Pharmaceutical Contract Manufacturing Market for Parenteral: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
23.3.4. Pharmaceutical Contract Manufacturing Market for Others: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation
24. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END-USERS
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Pharmaceutical Contract Manufacturing Market: Distribution by End-users, Current Year and 2035
24.3.1. Pharmaceutical Contract Manufacturing Market for Small Companies: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
24.3.2. Pharmaceutical Contract Manufacturing Market for Mid-sized Companies: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
24.3.3. Pharmaceutical Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
24.4. Data Triangulation and Validation
25. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Pharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, Current Year and 2035
25.3.1. Pharmaceutical Contract Manufacturing Market for Clinical: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
25.3.2. Pharmaceutical Contract Manufacturing Market for Commercial: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation
26. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Pharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions, Current Year and 2035
26.3.1. Pharmaceutical Contract Manufacturing Market in North America: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
26.3.2. Pharmaceutical Contract Manufacturing Market in Europe: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
26.3.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
26.3.2. Pharmaceutical Contract Manufacturing Market in Latin America: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
26.3.3. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
26.4. Data Triangulation and Validation
27. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Pharmaceutical Contract Manufacturing Market, by Leading Players
27.4. Data Triangulation and Validation
28. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES
28.1. Chapter Overview
28.2. Small Molecule and Large Molecule Drugs / Therapies
28.2.1. Comparison of General Characteristics
28.2.2. Comparison of Key Specifications
28.2.3. Comparison of Manufacturing Processes
28.2.4. Comparison of Key Manufacturing-related Challenges
29. CONCLUDING REMARKS
30. EXECUTIVE INSIGHTS
30.1. Chapter Overview
30.2. Ajinomoto Althea
30.2.1. Company Snapshot
30.2.2. Interview Transcript: Scott Goldstein, Former Director of Business Development
30.3. Bachem
30.3.1. Company Snapshot
30.3.2. Interview Transcript: Thomas Fruh, Former Chief Executive Officer
30.4. CiVentiChem
30.4.1. Company Snapshot
30.4.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer
30.5. CordenPharma
30.5.1. Company Snapshot
30.5.2. Interview Transcript: Roberto Margartia, Digitalization and Artificial Intelligence Manager
30.6. Helsinn Group
30.6.1. Company Snapshot
30.6.2. Interview Transcript: Allison Vavala, Former Director, Commercial Development
30.7. Novasep
30.7.1. Company Snapshot
30.7.2. Interview Transcript: Kevin Daley, Former Director, Pharmaceuticals Marketing
